Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728577 | 0.97 | PDE4B (0.48) | PDE4BCYP19A1NQO2BCHECNR2 | |
| SCHEMBL726599 | 0.94 | PDE4B (0.46) | PDE4BCYP19A1NQO2CNR2 | |
| SCHEMBL728717 | 0.94 | PDE4B (0.46) | PDE4BCYP19A1NQO2CNR2 | |
| SCHEMBL730965 | 0.93 | CYP19A1 (0.45) | PDE4BCYP19A1NQO2CNR2 | |
| SCHEMBL728726 | 0.92 | PDE4B (0.57) | PDE4BCYP19A1NQO2 | |
| SCHEMBL729276 | 0.92 | PDE4B (0.57) | PDE4BCYP19A1NQO2 | |
| SCHEMBL730897 | 0.92 | NQO2 (0.46) | PDE4BCYP19A1NQO2CNR2 | |
| SCHEMBL728871 | 0.91 | PDE4B (0.56) | PDE4BCYP19A1NQO2 | |
| SCHEMBL731012 | 0.91 | PDE4B (0.60) | PDE4BCYP19A1NQO2 | |
| SCHEMBL728605 | 0.88 | PDE4B (0.59) | PDE4BCYP19A1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8138205-B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | KALYPSYS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138205-B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | KALYPSYS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138205-B2 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 | KALYPSYS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2011093924-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885CYP19A1 1277/4885NQO2 624/4885 |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885CYP19A1 1277/4885NQO2 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.